云南白药2025年半年度报告(英文版)
2025 Interim Report of Yunnan Baiyao Group Co., Ltd. Yunnan Baiyao Group Co., Ltd. Interim Report 2025 August 20252025 Interim Report of Yunnan Baiyao Group Co., Ltd. 1 Section I Important Notes, Contents, and Definitions The Board of Directors (the “Board”), the Supervisory Committee and the directors, supervisors and senior management of the Company confirm the truthfulness, accuracy and completeness of the contents of this Interim Report and there are no misrepresentation, misleading statement or material omission from this Interim Report, and they accept joint and several responsibilities for the truthfulness, accuracy and completeness of the contents herein. Mr. Dong Ming, the person in charge of the Company, Mr. Ma Jia, the accounting officer, and Ms. Xu Jing, the head of accounting center (accounting supervisor), hereby declare that they warrant the truthfulness, accuracy, and completeness of the financial statements in this Interim Report. All directors of the Company attended the Board meeting in respect of considering and approving this Interim Report. The Company kindly requests investors to read through this Interim Report and pay special attention to “X. Risks and Countermeasures” in the “Section III Management Discussion and Analysis.” Investors are advised to pay attention to investment risks. The profit distribution plan considered and approved by the Board of Directors is as follows: Based on a total of 1,784,262,603 shares, a cash dividend of RMB 10.19 (tax inclusive) for every 10 shares will be paid to all shareholders, with no bonus shares issued (tax inclusive), and no capital reserve to increase the share capital. This report has been prepared in Chinese and translated into English. Should there be any discrepancies or misunderstandings between the two versions, the Chinese version shall prevail. 2025 Interim Report of Yunnan Baiyao Group Co., Ltd. 2 Contents Section I Important Notes, Contents, and Definitions ................................................. 1 Section II Company Profile and Key Financial Indicators .......................................... 5 Section III Management Discussion and Analysis ....................................................... 9 Section IV Corporate Governance, Environment and Society .................................. 46 Section V Significant Events ......................................................................................... 50 Section VI Changes in Shareholdings and Particulars about Shareholders ............ 71 Section VII Bonds .......................................................................................................... 77 Section VIII Financial Statements ................................................................................ 78 Section IX Other Reported Data .....................................................................
云南白药2025年半年度报告(英文版),点击即可下载。报告格式为PDF,大小3.35M,页数235页,欢迎下载。